This is a routine executive hire that strengthens medical leadership but does not alter the company's near-term clinical or financial trajectory. Monitor for future updates on HLP003 and HLP004 development timelines.
Price Chart
Executive Summary
Cybin Inc. (HELP) announced the appointment of Dr. Ken Kramer as Senior Vice President, Medical Affairs, effective immediately. Dr. Kramer brings over 25 years of neuroscience and medical affairs leadership experience from companies including Bristol Myers Squibb, Karuna Therapeutics, and AbbVie.
Key Facts
- Dr. Ken Kramer appointed as SVP, Medical Affairs at Helus Pharma (Cybin Inc.)
- Dr. Kramer has over 25 years of experience in neuroscience, including leadership roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie
- He previously led the global medical strategy for the first new schizophrenia treatment in over 70 years
- Appointment is effective immediately
- Helus Pharma is developing HLP003 (Phase 3 for MDD) and HLP004 (Phase 2 for GAD)
Financial Impact
No direct financial impact disclosed
Risk Factors
- No immediate financial or operational risk from this announcement
- Execution risk remains in clinical development of HLP003 and HLP004
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001833141-26-000022 |
| Document: cybininc-form6xk04x16x2026.htm | 0001833141-26-000022 |
| Document: 0001833141-26-000022-index-headers.html | 0001833141-26-000022 |
| Document: 0001833141-26-000022-index.html | 0001833141-26-000022 |
| Document: 0001833141-26-000022.txt | 0001833141-26-000022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.36 (+2.47%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.36 (−4.56%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.36 (−3.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers